Novel compositions comprising liposomes and biosurfactants

Abstract

The present invention relates to a liposomal composition comprising a biosurfactant and the use of the liposomal composition for encapsulating at least one cosmetic, pharmaceutical and / or nutraceutical active ingredient.

Description

[Technical field]

[0001] The present invention relates to a liposomal composition comprising a biosurfactant and to the use of the liposomal composition for encapsulating at least one cosmetic, pharmaceutical and / or nutraceutical active ingredient.

[0002] prior art U.S. Pat. No. 4,902,512 discloses liposomes formed from 2-O-α-decenoyl-α-L-rhamnopyranosyl-β-hydroxydecanoyl-β-hydroxydecanoic acid and 2-O-(2-O-α-decenoyl-α-rhamnopyranosyl)-α-L-rhamnopyranosyl-β-hydroxydecanoyl-β-hydroxydecanoic acid.

[0003] US Patent Publication No. 2019021338 discloses the application of peptides in rhamnolipid liposomes to plants, trees and shrubs to kill diseases and plant pathogens affecting those plants, trees and shrubs.

[0004] CN108158997 discloses the use of rhamnolipids for the preparation of membrane materials targeted to tumor cell liposomes, characterized in that the tumor cells are tumor cells expressing rhamnose receptors.

[0005] EP 2 654 779 A1 describes a liposome comprising a lipid bilayer membrane surrounding an aqueous core, the lipid bilayer comprising: (a) a non-glycosidic ceramide present in an amount of about 1% by weight to about 50% by weight based on the total weight of the liposome or lipid bilayer; (b) 1 to 5 types of lipids present in an amount of about 50% by weight to about 99% by weight based on the total weight of the liposome or lipid bilayer; A liposome comprising:

[0006] China Patent Publication No. 100536817 discloses a ceramide nanoliposome preparation, characterized in that the ceramide nanoliposome preparation contains the following components by weight percentage: 0.1-5% ceramide, 0.1-20% phospholipid, 10-70% glycerin and 25-80% water.

[0007] EP 1 138 311 A1 discloses proliposomal encapsulated preparations which are obtained by treating UV photoprotective filters and / or antioxidants with lecithin and / or phospholipids in a cosmetically acceptable solvent.

[0008] An object of the present invention is to provide a liposome composition which enables the solubilization of poorly soluble substances and has excellent long-term stability in terms of reprecipitation.

[0009] Description of the invention It has surprisingly been found that a liposome composition comprising a phospholipid and a biosurfactant solves the problems of the present invention.

[0010] The present invention therefore provides a composition comprising a liposome as recited in claim 1 and a biosurfactant.

[0011] The present invention further provides a method for encapsulating at least one cosmetic, pharmaceutical and / or nutraceutical active substance as recited in claim 11.

[0012] One advantage of the present invention is that the compositions according to the present invention have excellent stability.

[0013] Another advantage of the present invention is that the compositions according to the present invention are capable of keeping poorly soluble materials in solution.

[0014] A further advantage is that precipitation and / or crystallization of the active substance from, for example, the liposomes is prevented.

[0015] Another advantage of the present invention is that it increases the bioavailability of active agents, particularly poorly soluble active agents.

[0016] Another advantage of the present invention is that the compositions according to the present invention are easy to formulate in cosmetic, pharmaceutical and nutraceutical applications.

[0017] Another advantage of the present invention is that the irritation potential of the compounds contained in the compositions according to the present invention is reduced.

[0018] Another advantage of the present invention is that the compositions according to the present invention allow economical and sustainable processing at low temperatures.

[0019] Another advantage of the present invention is that the compositions according to the present invention chemically stabilize the active agent, eg, prevent degradation of the active agent.

[0020] Another advantage of the present invention is that the compositions according to the present invention enhance the compatibility of poorly soluble materials with other formulation ingredients.

[0021] Another advantage of the present invention is that the compositions according to the present invention are non-irritating to the skin.

[0022] Another advantage of the present invention is that the biosurfactant contained in the composition according to the invention stabilizes the liposome structure.

[0023] Another advantage of the present invention is that the compositions according to the present invention facilitate the incorporation of poorly soluble substances in pharmaceutical, cosmetic and nutraceutical applications.

[0024] Thus, the present invention provides: A) at least one phospholipid present at least partially in the bilayer of the liposome; B) at least one biosurfactant; C) water, and optionally D) at least one solvent selected from the group of alcohols and polyols containing at least 3 carbon atoms; The present invention provides a liposome composition comprising:

[0025] In the context of the present invention, "biosurfactants" is understood to mean any glycolipid produced by fermentation. The term "biosurfactant" also includes glycolipids that have been chemically or enzymatically modified after fermentation, as long as the glycolipid remains structurally a glycolipid.

[0026] Raw materials for producing biosurfactants which can be used are carbohydrates, in particular sugars, such as glucose, and / or lipophilic carbon sources, such as fats, oils, partial glycerides, fatty acids, fatty alcohols, long-chain saturated or unsaturated hydrocarbons.

[0027] Hereinafter, when an average value is given, it is a number average value unless otherwise specified.

[0028] Unless otherwise stated, percentages are percent by weight data.

[0029] Hereinafter, when measured values ​​are given, they are measured at a temperature of 25°C and a pressure of 1013 mbar unless otherwise specified.

[0030] A preferred composition according to the invention is characterized in that at least one phospholipid is selected from phosphatidylcholine (also called lecithin, often abbreviated as PC), phosphatidylethanolamine (also called cephalin, often abbreviated as PE), phosphatidic acid (also known as phosphatidate, often abbreviated as PA), phosphatidylserine (often abbreviated as PS), phosphoinositides such as phosphatidylinositol (often abbreviated as PI), phosphatidylinositol phosphate (often abbreviated as PIP), phosphatidylinositol diphosphate (often abbreviated as PIP2) and phosphatidylinositol triphosphate (often abbreviated as PIP3), and phosphosphingolipids such as ceramide phosphorylcholine (often abbreviated as SPH), ceramide phosphorylethanolamine (often abbreviated as Cer-PE) and ceramide phosphoryl lipids, preferably phosphatidylcholine.

[0031] Phospholipids are usually obtained from biological sources, such as plants and animals. Common industrial sources are soybeans, rapeseed, sunflower, chicken eggs, milk and fish eggs.

[0032] Preferably, the composition according to the invention is characterised in that it comprises phosphatidylcholine as component A), the phosphatidylcholine being preferably of vegetable origin, preferably from the group soybean, sunflower, rapeseed, lupine, pea and legumes, soybean and sunflower being particularly preferred, sunflower being most preferred.

[0033] The composition according to the invention preferably comprises as component B) at least one biosurfactant selected from rhamnolipids, sophorolipids, glucolipids, cellulose lipids, mannosylerythritol lipids and trehalose lipids, preferably rhamnolipids, sophorolipids, mannosylerythritol lipids and glucolipids, more preferably rhamnolipids, sophorolipids and glucolipids, more preferably rhamnolipids and glucolipids, most preferably rhamnolipids.

[0034] Biosurfactants are disclosed, for example, in European Patent Application Publication No. 0499434, U.S. Patent No. 7,985,722, International Publication No. 03 / 006146, Japanese Patent Application Publication No. 60-183032, German Patent Application Publication No. 19648439, German Patent Application Publication No. 19600743, Japanese Patent Application Publication No. 01-304034, Chinese Patent Application Publication No. 1337439, Japanese Patent Application Publication No. 2006-274233, Korean Patent Application Publication No. 2004033376, Japanese Patent Application Publication No. 2006-0 They can be produced as described in JP-A-83238, JP-A-2006-070231, WO-A-03 / 002700, FR-A-2740779, DE-A-2939519, US-A-7,556,654, FR-A-2855752, EP-A-1445302, JP-A-2008-062179 and JP-A-2007-181789 or the documents cited therein. Suitable biosurfactants can be obtained, for example, from Soliance, France.

[0035] Preferably, the composition according to the invention comprises as biosurfactant at least one selected from rhamnolipids, in particular mono-, di- or polyrhamnolipids, glucolipids, in particular mono-, di- or polyglucolipids, and sophorolipids, in particular mono-, di- or polysophorolipids, most preferably rhamnolipids.

[0036] The term "rhamnolipid" in the context of the present invention preferably refers in particular to rhamnolipids of the general formula (I) [ka] [In the formula, mRL=2, 1, or 0; nRL=1 or 0, R 1RL and R 2RL are, independently of one another, identical or different, organic radicals having 2 to 24, preferably 5 to 13, carbon atoms, in particular optionally branched, optionally substituted, in particular hydroxy-substituted, optionally unsaturated, in particular optionally mono-, di- or tri-unsaturated alkyl radicals, preferably pentenyl, heptenyl, nonenyl, undecenyl and tridecenyl, and (CH2) o -CH3, where o=1 to 23, preferably 4 to 12] and salts thereof.

[0037] When nRL=1, the glycosidic bond between the two rhamnose units is preferably in the α-configuration. The optically active carbon atom of the fatty acid is preferably present as the R-enantiomer (e.g., (R)-3-{(R)-3-[2-O-(α-L-rhamnopyranosyl)-α-L-rhamnopyranosyl]oxydecanoyl}oxydecanoate).

[0038] The term "dirhamnolipid" in the context of the present invention is understood to mean a compound of general formula (I) in which nRL=1 or a salt thereof.

[0039] The term "monorhamnolipid" in the context of the present invention is understood to mean a compound of general formula (I) in which nRL=0 or a salt thereof.

[0040] Each rhamnolipid is abbreviated according to the following nomenclature: "DiRL-CXCY" is a compound represented by the general formula (I) [wherein R 1RL and R 2RL One of them is (CH2)o -CH3 (where o=X-4) and the remaining group R 1 or R 2 is (CH2) o -CH3 (wherein o=Y-4) is understood to mean a dirhamnolipid of the formula:

[0041] "MonoRL-CXCY" refers to a compound represented by the general formula (I) [wherein R 1RL and R 2RL One of them is (CH2) o -CH3 (where o=X-4) and the remaining group R 1RL or R 2RL is (CH2) o -CH3 (wherein o=Y-4) is understood to mean a monorhamnolipid of the formula

[0042] Therefore, the nomenclature used does not distinguish between "CXCY" and "CYCX".

[0043] In the case of rhamnolipids with mRL=0, monoRL-CX or diRL-CX is used as appropriate.

[0044] When one of the subscripts X and / or Y is followed by ":Z", this means that each group R 1RL and / or R 2RL represents an unbranched, unsubstituted hydrocarbon group having X-3 or Y-3 carbon atoms and Z double bonds.

[0045] Methods for the preparation of related rhamnolipids are disclosed, for example, in EP-A-2 786 743 and EP-A-2 787 065.

[0046] Rhamnolipids applicable in the context of the present invention can also be produced by fermentation of Pseudomonas, preferably non-genetically modified cells, in particular Pseudomonas aeruginosa, a technique already disclosed in the 80s, for example as described in EP-A-0 282 942 and DE-A-4 127 908. Rhamnolipids produced in Pseudomonas aeruginosa cells modified by genetic modification to higher rhamnolipid titers can also be used in the context of the present invention, such cells being disclosed, for example, by Lei et al. in Biotechnol Lett. 2020 Jun; 42(6):997-1002.

[0047] Rhamnolipids produced by Pseudomonas aeruginosa are commercially available from Jeneil Biotech Inc., e.g. under the trade name Zonix, from Logos Technologies (Stepan acquired technology), e.g. under the trade name NatSurFac, from Biotensidion GmbH, e.g. under the trade name Rhapynal, from AGAE technologies, e.g. under the trade name R90, R95, R95Md, R95Dd, and from Locus Bio-Energy Solutions and Shanghai Yusheng Industry Co.Ltd., e.g. under the trade name Bio-201 Glycolipids.

[0048] The present invention preferably relates to a composition comprising a rhamnolipid as a biosurfactant, the biosurfactant component B) being one of the following: 51% by weight to 95% by weight, preferably 55% by weight to 80% by weight, particularly preferably 60% by weight to 70% by weight of diRL-C10C10 wherein the weight percentages are based on the total weight of all rhamnolipids present.

[0049] A preferred composition according to the invention is one which contains as biosurfactant the above-mentioned rhamnolipids in the form of: 0.5% by weight to 15% by weight, preferably 3% by weight to 12% by weight, particularly preferably 5% by weight to 10% by weight of diRL-C10C12:1 wherein the weight percentage is based on the sum of all rhamnolipids present.

[0050] Further preferred compositions according to the invention are those which contain as biosurfactants the above-mentioned rhamnolipids in the form of: 0.5 to 25% by weight, preferably 5 to 15% by weight, particularly preferably 7 to 12% by weight of diRL-C10C12 wherein the weight percentage is based on the sum of all rhamnolipids present.

[0051] Further preferred compositions according to the invention are those which contain as biosurfactants the above-mentioned rhamnolipids in the form of: 0.1% by weight to 25% by weight, preferably 2% by weight to 10% by weight, particularly preferably 4% by weight to 8% by weight of diRL-C8C10 wherein the weight percentage is based on the sum of all rhamnolipids present.

[0052] A still further preferred composition according to the invention is one which contains as biosurfactant the above-mentioned rhamnolipids in the form of: 0.1% to 5% by weight, preferably 0.5% to 3% by weight, particularly preferably 0.5% to 2% by weight of monoRL-C8C10 and / or preferably and 0.1% by weight to 5% by weight, preferably 0.5% by weight to 3% by weight, particularly preferably 0.5% by weight to 2% by weight of monoRL-C10C10 wherein the weight percentage is based on the sum of all rhamnolipids present.

[0053] Alternatively, the present invention preferably relates to a composition comprising a rhamnolipid as a biosurfactant, wherein the biosurfactant component B) is one of the following: 10% by weight to 50% by weight, preferably 20% by weight to 40% by weight, particularly preferably 25% by weight to 35% by weight of monoRL-C10C10 wherein the weight percentages are based on the total weight of all rhamnolipids present.

[0054] Other preferred compositions according to the invention preferably comprise, as biosurfactant, the above-mentioned rhamnolipids in the following form: 10% by weight to 30% by weight, preferably 12% by weight to 25% by weight, particularly preferably 15% by weight to 20% by weight of diRL-C10C10 wherein the weight percentage is based on the sum of all rhamnolipids present.

[0055] Other preferred compositions according to the invention are those which contain as biosurfactants the above-mentioned rhamnolipids in the form of: 10% by weight to 30% by weight, preferably 12% by weight to 25% by weight, particularly preferably 15% by weight to 20% by weight of monoRL-C8C10 wherein the weight percentage is based on the sum of all rhamnolipids present.

[0056] Other preferred compositions according to the invention are those which contain as biosurfactants the above-mentioned rhamnolipids in the form of: 3% by weight to 25% by weight, preferably 5% by weight to 20% by weight, particularly preferably 10% by weight to 15% by weight of monoRL-C10C12:1 wherein the weight percentage is based on the sum of all rhamnolipids present.

[0057] Other preferred compositions according to the invention are those which contain as biosurfactants the above-mentioned rhamnolipids in the form of: 1% by weight to 15% by weight, preferably 2% by weight to 10% by weight, particularly preferably 3% by weight to 8% by weight of diRL-C10C12 wherein the weight percentage is based on the sum of all rhamnolipids present.

[0058] In the context of the present invention, the term "sophorolipid" preferably refers to a sophorolipid having the general formula (IIa) and (IIb) [ka] [In the formula, R 1SL is H or CO-CH3, R 2SL is H or CO-CH3, R 3SL is a divalent organic moiety containing 6 to 32 carbon atoms, which is unsubstituted or substituted with a hydroxyl functional group, unbranched, and optionally contains 1 to 3 double or triple bonds; R 4SL is H, CH3 or a monovalent organic group, which contains 2 to 10 carbon atoms, is unsubstituted or substituted with a hydroxyl functional group, is unbranched, and optionally contains 1 to 3 double or triple bonds; nSL is 1 or 0] and salts thereof.

[0059] The sophorolipid can be used according to the invention in its acid form or in its lactone form.

[0060] A preferred composition according to the present invention contains sophorolipids in which the weight ratio of lactone type to acid type is in the range of 20:80 to 80:20, and particularly preferably in the range of 30:70 to 40:60.

[0061] To measure the content of acid or lactone sophorolipids in a formulation, see EP 1411111, page 8, paragraph

[0053] .

[0062] In the context of the present invention, the term "glucolipid" refers to a compound of the general formula (III) [ka] [In the formula, mGL=1 or 0, R 1GL and R 2GL are independently of one another identical or different organic radicals having 2 to 24 carbon atoms, in particular optionally branched, optionally substituted, in particular hydroxy-substituted, optionally unsaturated, in particular optionally mono-, di- or tri-unsaturated alkyl radicals, preferably pentenyl, heptenyl, nonenyl, undecenyl and tridecenyl, and (CH2) o -CH3 (wherein o=1 to 23, preferably 4 to 12) or a salt thereof.

[0063] Each glucolipid is abbreviated according to the following nomenclature: "GL-CXCY" is a compound represented by the general formula (III) [wherein R 1GL and R 2GL One of them is (CH2) o -CH3 (where o=X-4) and the remaining group R 1GL or R 2GL is (CH2) o -CH3 (wherein o=Y-4) is understood to mean a glucolipid of the formula:

[0064] Therefore, the nomenclature used does not distinguish between "CXCY" and "CYCX".

[0065] When one of the subscripts X and / or Y is followed by ":Z", this means that each group R 1GL and / or 2GLis an unbranched, unsubstituted hydrocarbon group having X-3 or Y-3 carbon atoms and Z double bonds.

[0066] The method for producing glucolipids can be carried out as described in WO2019154970.

[0067] It is preferred that the composition according to the invention comprises at least one solvent of component D), in particular in that case the biosurfactant of component B) is selected from rhamnolipids.

[0068] Preferred compositions according to the invention are characterized in that at least one solvent of component D) is selected from the alcohols of the group consisting of alkanols and alkenols.

[0069] Preferred alkanols and alkenols preferably have 3 to 30 carbon atoms. They may be linear, such as, for example, propanol, butanol, pentanol, hexanol, heptanol, octanol, 1-dodecanol, 1-tetradecanol, 1-hexadecanol, 1-octadecanol, 1-docosanol, cis-9-hexadecen-1-ol, cis-9-octadecen-1-ol, trans-9-octadecen-1-ol, cis,cis-9,12-octadecadien-1-ol, 6,9,12-octadecatrien-1-ol, or branched, such as, for example, 16-methylheptadecan-1-ol, 3-methyl-1-butanol, and octyldodecanol, but linear alkanols are preferred.

[0070] Preferred compositions according to the invention are characterized in that the at least one solvent is selected from diols and triols, preferably having 3 to 30 carbon atoms, preferably glycols, more preferably selected from the group consisting of propanediol, butanediol, preferably 1,3-butanediol, pentanediol, preferably 1,2-pentanediol, hexanediol, preferably 1,2-hexanediol, octanediol, preferably 1,2-octanediol, decanediol, preferably 1,2-decanediol and glycerin, with glycerin being particularly preferred.

[0071] The composition according to the invention can be advantageously used for the encapsulation and / or stabilization of active ingredients. Thus, in the present invention, the composition according to the invention is E) at least one cosmetic, pharmaceutical and / or nutraceutical active ingredient, preferably having a solubility in water at 25° C. and 1 bar of less than 1 mg / ml, preferably less than 0.1 mg / ml; It is preferred if the

[0072] Preferably, component E) of the composition according to the invention is selected from cosmetic active ingredients.

[0073] The cosmetically, pharma- ceutical and / or nutraceutical active ingredients contained in the composition according to the invention are preferably at least partially contained in the bilayer of the liposomes contained in the composition according to the invention.

[0074] Pharmaceutically and / or nutraceutical active ingredients preferably included in this context are selected from glycogen, ceramides, sphingoid bases, sterols, peptides, amino acids, phenols, polyphenols, vitamins, plant or algae extracts and cosmetic oils, with ceramides, sphingoid bases and sterols being particularly preferred.

[0075] Ceramides, sphingoid bases, sterols, peptides, polyphenols, vitamins, plant extracts and cosmetic oils may all be included in compositions according to the invention.

[0076] The preferred ceramides contained in the composition according to the present invention are selected from the group comprising, preferably consisting of, ceramide NP, ceramide AP, ceramide EOP, ceramide NDS, ceramide ADS, ceramide EODS, ceramide NS, ceramide AS, ceramide EOS, ceramide NH, ceramide AH and ceramide EOH, and are preferably selected from the group comprising, preferably consisting of, ceramide NP, ceramide AP, ceramide NS, ceramide EOP and ceramide EOS.The nomenclature of ceramides is commonly used and is described in detail in Farwick et al. Developments in Ceramide Identification, Synthesis, Function and Nomenclature, Cosmet Toil 2009; 124: 63-72.

[0077] Preferred sphingoid bases included in the compositions according to the invention are selected from the group comprising, preferably consisting of, sphingosine, sphinganine, 6-hydroxysphingosine and phytosphingosine.

[0078] Preferred sterols for inclusion in the composition according to the invention are selected from the group including, and preferably consisting of, cholesterol, 7-dehydrocholesterol, cholesterol potassium sulfate, cholesteryl succinate, 25-hydroxy-7-dehydrocholesterol, ergosterol, fucosterol, hopanoids, hydroxysteroids, phytosterols such as campesterol, sitosterol and stigmasterol, steroids and zoosterols, with cholesterol being particularly preferred.

[0079] Preferred peptides included in the composition according to the invention are selected from the group including, preferably consisting of, palmitoyl hexapeptide-12, palmitoyl oligopeptide, palmitoyl pentapeptide-3, palmitoyl tetrapeptide-7, palmitoyl tripeptide-1, collagen, elastin, epidermal growth factor (EGF), epithalon and fibronectin.

[0080] Preferred amino acids for inclusion in the composition according to the invention are selected from the group comprising, preferably consisting of, proteinogenic amino acids, preferably alanine, valine, isoleucine, leucine, methionine, phenylalanine, tyrosine and tryptophan.

[0081] Preferred phenols and polyphenols included in the compositions according to the invention are selected from the group including, and preferably consisting of, resveratrol, quercetin, rutin, ellagic acid, apigenin, phloretin, caftaric acid, caffeic acid phenylethyl ester, pterostilbene, luteolin, fisetin, honokiol, ferulic acid and sinapic acid.

[0082] Preferred vitamins comprised in the composition according to the invention are selected from the group including, preferably consisting of, coenzyme q10 (ubiquinone), biotin, vitamin A, retin A, retinoids, retinol, retinaldehyde, retinol palmitate, retinyl ascorbate, retinyl palmitate, retinyl retinoate, vitamin D, cholecalciferol, ergocalciferol, vitamin E, preferably α-, β-, γ- and δ-tocopherol, tocopherol, tocopherol acetate, tocopheryl acetate, tocopheryl linoleate, tocopheryl linoleate, tocopheryl linoleate / oleate, tocopheryl nicotinate, tocopheryl succinate, tocotrienols, vitamin K and vitamin C, preferably ascorbyl palmitate.

[0083] Preferred plant or algae extracts for inclusion in the composition according to the invention are aloe (especially vera) extract, aesculus hippocastanum extract, calendula officinalis flower extract, centella asiatica extract, bactiol, ascophyllum nodosum extract, acemannan, coleus barbatus extract, cranberry seed extract, ginkgo biloba leaf extract, ginseng extract, grapefruit peel extract, green tea extract, hordeum vulgare extract, horse chestnut extract, oryza sativa (rice) extract, pectin, polygonum cuspidatum extract, polygonum cuspidatum extract, polysaccharide ... cuspidatum root extract, pomegranate extract, spirulina extract, squalene, St. John's wort extract, willow bark extract, capsaicin, chili pepper extract, glycyrrhiza glabra extract, madecassoside, rosmarinus officinalis extract, ruscogenin, carotenoids, preferably astaxanthin, beta-carotene, canthaxanthin, capsanthin, capsorubin, cryptoxanthin, lutein, luteoxanthin, lycopene and zeaxanthin, chamomilla recutita (chamomile) flower extract, sesamin, pyrus malus (pyrus) flower extract, malus fruit extract, baicalein, puerarin, phloridzin, 1,4-dicaffeoylquinic acid, myricetin-3-o-β-rhamnoside, dihydromyricetin, diosmetin, 6-gingerol and mangunolol.

[0084] Preferred cosmetic oils for inclusion in the composition according to the invention are argan oil, almond oil, blackcurrant oil, chia oil, cannabis sativa l. oil, avocado oil (persea gratissima), caprylic / capric triglyceride, cottonseed oil, hemp oil, canola oil, marula oil, peach kernel oil, perilla oil, pomegranate seed oil, pumpkin seed oil, seabuckthorn oil, palm oil, palm-derived fatty acids, mountain soybean oil, helianthus annuus seed oil, jojoba oil, macadamia nut oil, persea gratissima oil, triticum vulgare (wheat) germ oil, grape seed oil, MCT oil, grapefruit oil, ginger oil, butyrospermum parkii (butyrospermum parkii) oil, oleaginous acid ... parkii (shea) butter, camellia sinensis seed oil, cocoa butter, coconut oil and evening primrose oil.

[0085] An advantage of the present invention is that a large number of cosmetic, pharmaceutical and / or nutraceutical active ingredients can be included in the compositions according to the invention.

[0086] Preferably, the composition according to the invention comprises as component E) at least one ceramide and cholesterol, more preferably at least one ceramide, at least one sphingoid base and cholesterol.

[0087] In this context, the weight ratio of the sum of all ceramides and optionally all sphingoid bases contained in the composition according to the invention to cholesterol is preferably in the range of 1000:1 to 1:100, more preferably 100:1 to 1:10, most preferably 10:1 to 1:1, respectively.

[0088] The composition according to the present invention is a liposome composition and therefore contains liposomes. The liposomes contained in the composition according to the present invention preferably have an average particle size of 15 nm to 800 nm, preferably 50 nm to 500 nm, more preferably 60 nm to 350 nm, and even more preferably 80 nm to 240 nm.

[0089] Photon correlation spectroscopy is employed to measure the average particle size. Measurements are performed using a Zetasizer Nano ZS90, Malvern Instruments Ltd., UK, following the manufacturer's instructions. The Z-average is the intensity-weighted average hydrodynamic dimension of an ensemble of particles measured by dynamic light scattering (DLS). The Z-average is derived from a cumulant analysis of the measured correlation curve, where a single particle size is assumed and a single exponential fit is applied to the autocorrelation function (see Zetasizer Nano ZS90 User Manual MAN0485-1-1 09 June 2017).

[0090] A preferred composition according to the present invention is one in which the composition A) in an amount of 0.1% by weight to 60% by weight, preferably 1% by weight to 40% by weight, more preferably 5% by weight to 25% by weight, B) in an amount of 0.1% by weight to 60% by weight, preferably 1% by weight to 40% by weight, more preferably 5% by weight to 25% by weight, C) in an amount of 10% by weight to 95% by weight, preferably 20% by weight to 85% by weight, more preferably 35% by weight to 75% by weight, and optionally D) in an amount of 0.1% by weight to 80% by weight, preferably 1% by weight to 60% by weight, more preferably 5% by weight to 30% by weight, and optionally E) in an amount of 0.05% by weight to 20% by weight, preferably 0.1% by weight to 10% by weight, more preferably 0.5% by weight to 5% by weight. wherein the weight percentages are based on the total composition.

[0091] This is similar to a concentrated stock of the liposomal composition.

[0092] If component E) is included, this preferred composition according to the invention is very well suited as a storage vehicle for cosmetic, pharmaceutical and / or nutraceutical active ingredients.

[0093] These compositions facilitate easy handling of the active substances and easy formulation of end-user formulations.

[0094] The present invention therefore further relates to a formulation, in particular a cosmetic, pharmaceutical, dermatological or nutraceutical formulation, comprising a composition according to the invention, most preferably a cosmetic formulation.

[0095] The formulation according to the invention may further comprise at least one additional ingredient selected from the following group: Emollients, emulsifier, Thickeners / viscosity modifiers / stabilizers, UV light protection filter, Antioxidants, Hydrotropes, Solids and fillers, Film-forming agents, Pearlescent additives, Active ingredients in deodorants and antiperspirants, Insect repellents, Self-tanning agents, Preservatives, Conditioning agents, fragrance, dye, Odor absorbers, Superfatting agents, Other solvents.

[0096] Substances which can be used as representatives of the individual groups are known to the person skilled in the art and are described, for example, in German application DE102008001788.4, which is incorporated herein by reference and thus forms part of the present disclosure.

[0097] With regard to further optional ingredients and the amounts of these ingredients to be used, explicit reference is made to the relevant handbooks known to the person skilled in the art, for example K. Schrader, “Grundlagen und Rezepturen der Kosmetika [Cosmetics - fundamentals and formulations]”, 2nd edition, pages 329-341, Huethig Buch Verlag Heidelberg.

[0098] The amount of a particular additive will be determined by the intended use.

[0099] Typical boundary formulations for each application are known prior art and are described, for example, in the brochures of manufacturers of specific bases and active ingredients.These existing formulations can generally be adopted as is.However, if necessary, desired changes can be made for adjustment and optimization by simple testing without complication.

[0100] A preferred formulation according to the invention is one in which the formulation A) in an amount of 0.0001% by weight to 6% by weight, preferably 0.001% by weight to 4% by weight, more preferably 0.005% by weight to 2.5% by weight, B) in an amount of 0.0001% by weight to 6% by weight, preferably 0.001% by weight to 4% by weight, more preferably 0.005% by weight to 2.5% by weight, C) in an amount of 20% by weight to 99% by weight, preferably 30% by weight to 95% by weight, more preferably 50% by weight to 90% by weight, and optionally D) in an amount of 0.0001% to 30% by weight, preferably 0.001% to 25% by weight, more preferably 0.005% to 20% by weight, and optionally E) in an amount of 0.00005% by weight to 40% by weight, preferably 0.0001% by weight to 20% by weight, more preferably 0.0005% by weight to 0.5% by weight. wherein the weight percentages are based on the total formulation, and is preferably characterized in that the weight ratio of component C) to component A) is greater than 10, preferably greater than 30.

[0101] Components A) to E) are the same as those contained in the composition according to the invention. D) and E) can be contained in a higher proportion compared to the other components than in the composition according to the invention. For example, it is common to add additional solvents (component D)) or cosmetic oils (component E)) to the final customer formulation.

[0102] Particularly preferred compositions according to the invention, and also preferred formulations according to the invention, are characterized by a pH in the range from 4.0 to 8.0, preferably from 4.5 to 7.5, particularly preferably from 4.5 to 6.5.

[0103] "pH" in the context of this invention is defined as the value measured on the composition at 22°C after stirring for 5 minutes using a pH electrode calibrated in accordance with ISO 4316 (1977).

[0104] The present invention further relates to a method for encapsulating at least one cosmetic, pharmaceutical and / or nutraceutical active ingredient, comprising: I) providing and combining at least one phospholipid A), at least one biosurfactant B), at least one cosmetic, pharmaceutical and / or nutraceutical active ingredient E) and, optionally, at least one solvent D) selected from the group of alcohols and polyols containing at least 3 carbon atoms, II) heating the provided components to a temperature in the range of 50°C to 100°C, preferably 60°C to 95°C, more preferably 70°C to 90°C, and even more preferably 75°C to 90°C; III) heating water C) to a temperature in the range of 50° C. to 100° C., preferably 60° C. to 95° C., more preferably 70° C. to 90° C., even more preferably 75° C. to 90° C., and combining the water with the ingredients provided in step I). The present invention relates to a method comprising the steps of:

[0105] Preferably, the same preferred components A) to E) as described above for the composition according to the invention are used in the process according to the invention, in the same preferred embodiments.

[0106] The combining of components A) to E) in step III) of the process of the present invention is preferably carried out with stirring, preferably with homogenization by stirring.

[0107] Preferably, an additional homogenization is carried out, which comprises, for example, high shear rate homogenization with an agitator speed of 3,000 rpm to 25,000 rpm, typically 5,000 rpm to 20,000 rpm, and / or high pressure homogenization, preferably at 100 bar to 1000 bar, typically 500 bar to 700 bar.

[0108] The present invention further relates to the use of at least one composition according to the invention for encapsulating at least one cosmetic, pharmaceutical and / or nutraceutical active ingredient. The encapsulated active ingredient is preferably one of component E) of the composition according to the invention.

[0109] The examples presented below are intended to illustrate the present invention, and are not intended to limit the present invention to the embodiments specified in the examples. The scope of the present invention is clear from the entire specification and claims.

[0110] Working Example: Rhamnolipids were prepared as described in EP 3023431 A1.

[0111] The sophorolipid used was sophorolipid REWOFERM SL ONE from Evonik, with a lactone to acid ratio of 40:60.

[0112] Glucolipid was produced by fermentation according to Example 2 of WO2019154970.

[0113] Example 1: Preparation of liposomes containing rhamnolipids (according to the invention) To prepare the liposome composition according to Example 1, lecithin was stirred with glycerin and rhamnolipid at a temperature of 85° C. for 60 minutes.

[0114] Water preheated to 85°C was added to the above composition while homogenizing for 4 minutes. Finally, the preservative Optiphen BD was added while homogenizing for an additional minute.

[0115] The final liposome composition contents were as follows; a total of 100 grams was prepared: 11.5% by weight of sunflower lecithin, 22.0% by weight of glycerin, 11.5% by weight of rhamnolipids, 54.0% by weight of water, 1.0% by weight of preservative Optiphen BD (benzyl alcohol, benzoic acid, dehydroacetic acid).

[0116] The particle size and polydispersity index (PDI) of lipid vesicles produced by this method were confirmed using photon correlation spectroscopy (PCS, Zetasizer Nano ZS90, Malvern Instruments Ltd., UK) according to the manufacturer's instructions; the production process was terminated after the average particle size was approximately 190 nm in diameter and PDI ≤ 0.2.

[0117] Example 2: Preparation of liposomes containing rhamnolipid and loaded with ceramide NP, phytosphingosine and cholesterol as active ingredients (according to the invention) To prepare the liposome composition according to Example 2, lecithin was stirred with glycerin and rhamnolipid for 60 minutes at a temperature of 85° C. The active ingredient was added and stirred for a further 60 minutes.

[0118] Water preheated to 85°C was added to the above composition while homogenizing for 4 minutes. Finally, the preservative Optiphen BD was added while homogenizing for an additional minute.

[0119] The final liposome composition contents were as follows; a total of 100 grams was prepared: 11.5% by weight of sunflower lecithin, 22.0% by weight of glycerin, 11.5% by weight of rhamnolipids, 1.2 wt.% ceramide NPs; 1.2% by weight of phytosphingosine, 0.2% by weight cholesterol, 51.4% by weight of water, 1.0% by weight of preservative Optiphen BD (benzyl alcohol, benzoic acid, dehydroacetic acid).

[0120] The particle size and polydispersity index (PDI) of lipid vesicles produced by this method were confirmed using photon correlation spectroscopy (PCS, Zetasizer Nano ZS90, Malvern Instruments Ltd., UK) according to the manufacturer's instructions; the production process was terminated after the average particle size was approximately 160 nm in diameter and PDI ≤ 0.2.

[0121] Example 3: Preparation of liposomes containing rhamnolipid and loaded with ceramide NP, phytosphingosine and cholesterol as active ingredients (according to the invention) To prepare the liposome composition according to Example 3, lecithin is stirred with glycerin, 1,2-pentanediol, 1,3-butanediol and rhamnolipid for 60 minutes at a temperature of 85° C. The active ingredient is added and stirred for a further 60 minutes.

[0122] Water preheated to 85°C is added to the above composition while homogenizing for 4 minutes.

[0123] The final liposome composition contents are as follows; a total of 100 grams is prepared: 11.5% by weight of sunflower lecithin, 14% by weight of glycerin, 2.0% by weight of 1,2-pentanediol, 3.5% by weight of 1,3-butanediol, 11.5% by weight of rhamnolipids, 1.2 wt.% ceramide NPs; 1.2% by weight of phytosphingosine, 0.2% by weight cholesterol, 54.9% water by weight.

[0124] The particle size and polydispersity index (PDI) of lipid vesicles produced by this method are confirmed using photon correlation spectroscopy (PCS, Zetasizer Nano ZS90, Malvern Instruments Ltd., UK) according to the manufacturer's instructions; the production process is terminated after the average particle size is approximately 200 nm in diameter and PDI = 0.2.

[0125] Example 4: Preparation of liposomes containing polysorbate-80 (not according to the invention) To prepare the liposome composition according to Example 4, lecithin was stirred with glycerin and polysorbate-80 at a temperature of 85° C. for 60 minutes.

[0126] Water preheated to 85°C was added to the above composition while homogenizing for 4 minutes. Finally, the preservative Optiphen BD was added while homogenizing for an additional minute.

[0127] The final liposome composition contents were as follows; a total of 100 grams was prepared: 11.5% by weight of sunflower lecithin, 22% by weight of glycerin, 11.5% by weight of polysorbate-80, 54% by weight of water, 1% by weight of the preservative Optiphen BD (benzyl alcohol, benzoic acid, dehydroacetic acid).

[0128] The particle size and polydispersity index (PDI) of lipid vesicles produced by this method were confirmed using photon correlation spectroscopy (PCS, Zetasizer Nano ZS90, Malvern Instruments Ltd., UK) according to the manufacturer's instructions; the production process was terminated after the average particle size was approximately 106 nm in diameter and PDI ≤ 0.2.

[0129] Example 5: Preparation of liposomes containing polysorbate-80 and loaded with ceramide NP, phytosphingosine and cholesterol as active ingredients (not according to the invention) To prepare the liposome composition according to Example 5, lecithin was stirred with glycerin and polysorbate-80 for 60 minutes at a temperature of 85° C. The active ingredient was added and stirred for another 60 minutes.

[0130] Water preheated to 85°C was added to the above composition while homogenizing for 4 minutes. Finally, the preservative Optiphen BD was added while homogenizing for an additional minute.

[0131] The final liposome composition contents were as follows; a total of 100 grams was prepared: 11.5% by weight of sunflower lecithin, 22% by weight of glycerin, 11.5% by weight of polysorbate-80, 1.2 wt.% ceramide NPs; 1.2% by weight of phytosphingosine, 0.2% by weight cholesterol, 51.4% by weight of water, 1% by weight of the preservative Optiphen BD (benzyl alcohol, benzoic acid, dehydroacetic acid).

[0132] The particle size and polydispersity index (PDI) of lipid vesicles produced by this method were confirmed using photon correlation spectroscopy (PCS, Zetasizer Nano ZS90, Malvern Instruments Ltd., UK) according to the manufacturer's instructions; the production process was terminated after the average particle size was approximately 160 nm in diameter and PDI < 0.3.

[0133] Example 5b: Preparation of surfactant-free liposomes loaded with ceramide NP, phytosphingosine and cholesterol as active ingredients (not according to the invention) To prepare the liposome composition according to Example 5b, lecithin was stirred with glycerin for 60 minutes at a temperature of 85° C. The active ingredient was added and stirred for another 60 minutes.

[0134] Water preheated to 85°C was added to the above composition while homogenizing for 4 minutes. Finally, the preservative Optiphen BD was added while homogenizing for an additional minute.

[0135] The final liposome composition contents were as follows; a total of 100 grams was prepared: 11.5% by weight of sunflower lecithin, 22% by weight of glycerin, 1.2 wt.% ceramide NPs; 1.2% by weight of phytosphingosine, 0.2% by weight cholesterol, 62.9% by weight of water, 1% by weight of the preservative Optiphen BD (benzyl alcohol, benzoic acid, dehydroacetic acid).

[0136] It was not possible to prepare a stable liposome composition with the above ingredients, and therefore it was not possible to examine the particle size or PDI.

[0137] Example 6: Preparation of liposomes containing rhamnolipids and loaded with caprooyl phytosphingosine as active ingredient (according to the invention) To prepare the liposome composition according to Example 11, lecithin was stirred with glycerin and rhamnolipid for 60 minutes at a temperature of 85° C. The active ingredient was added and stirred for a further 60 minutes.

[0138] Water preheated to 85°C was added to the above composition while homogenizing for 4 minutes. Finally, the preservative Optiphen BD was added while homogenizing for an additional minute.

[0139] The final liposome composition contents were as follows; a total of 100 grams was prepared: 8.7% by weight of sunflower lecithin; 18.0% by weight of glycerin, 8.7% by weight of rhamnolipids, 3.2% by weight of caprooyl phytosphingosine; 60.4% by weight of water, 1.0% by weight of preservative Optiphen BD (benzyl alcohol, benzoic acid, dehydroacetic acid).

[0140] The particle size and polydispersity index (PDI) of lipid vesicles produced by this method were confirmed using photon correlation spectroscopy (PCS, Zetasizer Nano ZS90, Malvern Instruments Ltd., UK) according to the manufacturer's instructions; the production process was terminated after the average particle size was approximately 218 nm in diameter and PDI ≤ 0.3.

[0141] Example 7: Preparation of liposomes containing polysorbate-80 and loaded with caproyl phytosphingosine as the active ingredient (not according to the invention) To prepare the liposome composition according to Example 12, lecithin was stirred with glycerin and polysorbate-80 for 60 minutes at a temperature of 85° C. The active ingredient was added and stirred for an additional 60 minutes.

[0142] Water preheated to 85°C was added to the above composition while homogenizing for an additional 4 minutes. Finally, the preservative Optiphen BD was added while homogenizing for an additional minute.

[0143] The final liposome composition contents were as follows; a total of 100 grams was prepared: 8.7% by weight of sunflower lecithin; 18.0% by weight of glycerin, 8.7% by weight of polysorbate-80, 3.2% by weight of caprooyl phytosphingosine; 60.4% by weight of water, 1.0% by weight of preservative Optiphen BD (benzyl alcohol, benzoic acid, dehydroacetic acid).

[0144] The particle size and polydispersity index (PDI) of lipid vesicles produced by this method were confirmed using photon correlation spectroscopy (PCS, Zetasizer Nano ZS90, Malvern Instruments Ltd., UK) according to the manufacturer's instructions; the production process was terminated after the average particle size was approximately 200 nm in diameter and PDI 0.5.

[0145] Compared to Example 6, the liposome composition of Example 7 demonstrated lack of adequate stability due to its high PDI.

[0146] Example 8: Reduction of crystallization of active substances by biosurfactants in liposomes during storage The compositions of Example 2, Example 3, and Example 5 were stored at various temperatures, and the occurrence of crystals at various times was examined: In Example 5, crystallization was observed after 2 weeks of storage at room temperature and at 40° C., whereas in Examples 2 and 3, no crystallization was observed at all.

[0147] Example 8b: Reduction of active agent segregation by biosurfactants in liposomes during storage The following liposome composition is prepared according to example H2 of EP 1 138 311: [Table 1]

[0148] Separation of 2-ethylhexyl salicylate is observed in Preparations V1 and V2 after 28 weeks of storage at room temperature and after 12 weeks of storage at 40°C, but no separation is observed in 8Rr, 8Rs, 8Rg, 8RR, 8RS, and 8RG.

[0149] Example 8c: Reduction of active agent segregation by biosurfactants in liposomes during storage The following liposome composition is prepared according to example H2 of EP 1 138 311 A1 without squalane: [Table 2]

[0150] Separation of salicylic acid 2-ethylhexyl ester is observed in formulation V3 after 28 weeks at room temperature and after 9 weeks at 40° C., whereas no separation is observed in 9Rr, 9Rs and 9Rg.

[0151] Example 9: Preparation of liposomes containing glucolipids and loaded with ceramide NP, phytosphingosine and cholesterol as active ingredients (according to the present invention) To prepare the liposome composition according to Example 9, the lecithin is stirred with the glycerin and the glucolipid for 60 minutes at a temperature of 85° C. The active ingredient is added and stirred for another 60 minutes.

[0152] Water preheated to 85°C is added to the above composition while homogenizing for 4 minutes. Finally, the preservative Optiphen BD is added while homogenizing for an additional minute.

[0153] The final liposome composition contents are as follows; a total of 100 grams is prepared: Glucolipids were prepared as described in the Examples of WO2019154970. 11.5% by weight of sunflower lecithin, 22.0% by weight of glycerin, 11.5% by weight of glucolipids, 1.2 wt.% ceramide NPs; 1.2% by weight of phytosphingosine, 0.2% by weight cholesterol, 51.4% by weight of water, 1.0% by weight of preservative Optiphen BD (benzyl alcohol, benzoic acid, dehydroacetic acid).

[0154] The particle size and polydispersity index (PDI) of lipid vesicles produced by this method are confirmed using photon correlation spectroscopy (PCS, Zetasizer Nano ZS90, Malvern Instruments Ltd., UK) according to the manufacturer's instructions; the production process is terminated after the average particle size is approximately 200 nm in diameter and PDI ≦ 0.2.

[0155] Example 10: Preparation of liposomes containing sophorolipids and loaded with ceramide NP, phytosphingosine and cholesterol as active ingredients (according to the present invention) To prepare the liposome composition according to Example 10, the lecithin is stirred with the glycerin and the sophorolipid for 60 minutes at a temperature of 85° C. The active ingredient is added and stirred for another 60 minutes.

[0156] Water preheated to 85°C is added to the above composition while homogenizing for 4 minutes. Finally, the preservative Optiphen BD is added while homogenizing for an additional minute.

[0157] The final liposome composition contents are as follows; a total of 100 grams is prepared: The sophorolipid used was sophorolipid "SL 18" manufactured by Ecover, with an acid to lactone ratio of 70:30. 11.5% by weight of sunflower lecithin, 22% by weight of glycerin, 11.5% by weight of sophorolipid; 1.2 wt.% ceramide NPs; 1.2% by weight of phytosphingosine, 0.2% by weight cholesterol, 51.4% by weight of water, 1% by weight of the preservative Optiphen BD (benzyl alcohol, benzoic acid, dehydroacetic acid).

[0158] The particle size and polydispersity index (PDI) of lipid vesicles produced by this method are confirmed using photon correlation spectroscopy (PCS, Zetasizer Nano ZS90, Malvern Instruments Ltd., UK) according to the manufacturer's instructions; the production process is terminated after the average particle size is approximately 200 nm in diameter and PDI ≦ 0.2.

[0159] Example 11: Preparation of liposomes containing PEG-6 caprylic / capric glyceride and loaded with ceramide NP, phytosphingosine and cholesterol as active ingredients (not according to the invention) The final liposome composition contents are as follows; a total of 100 grams is prepared: 11.5% by weight of sunflower lecithin, 22% by weight of glycerin, 11.5% by weight of PEG-6 caprylic / capric glyceride; 1.2 wt.% ceramide NPs; 1.2% by weight of phytosphingosine, 0.2% by weight cholesterol, 51.4% by weight of water, 1% by weight of the preservative Optiphen BD (benzyl alcohol, benzoic acid, dehydroacetic acid).

[0160] To prepare the liposome composition according to Example 9, lecithin is stirred with glycerin and PEG-6 caprylic / capric glyceride for 60 minutes at a temperature of 85° C. The active ingredient is added and stirred for another 60 minutes.

[0161] Water preheated to 85°C is added to the above composition while homogenizing for 4 minutes. Finally, the preservative Optiphen BD is added while stirring for another minute.

[0162] The particle size and polydispersity index (PDI) of lipid vesicles produced by this method are confirmed using photon correlation spectroscopy (PCS, Zetasizer Nano ZS90, Malvern Instruments Ltd., UK) according to the manufacturer's instructions; the production process is terminated after the average particle size is approximately 200 nm in diameter and PDI ≦ 0.2.

[0163] Example 12: Reduction of recrystallization by biosurfactants in liposomes upon repeated freeze-thaw cycles The liposome compositions of Examples 9 to 11 are deep frozen in a refrigerator at −20° C. for 3 hours and then thawed in a water bath at 30° C. This procedure is repeated four times, and then the composition is analyzed for crystallization.

[0164] In Example 11, crystallization is observed after repeated freeze-thaw cycles, whereas in Examples 9 and 10, no recrystallization is observed.

[0165] Example 13: Enhancement of liposome stability by biosurfactants in liposome compositions The physical stability of the formulations and that of the resulting liposomes are investigated by measuring the pH value, particle size and polydispersity using a pH meter and photon correlation spectroscopy (PCS, Zetasizer Nano ZS90, Malvern Instruments Ltd., UK) according to the manufacturer's instructions.

[0166] The formulations are stored at 4°C, room temperature and 40°C and measured over a period of 48 weeks.

[0167] A change in pH of more than ±2 units, an increase in liposome size of more than 400 nm, and / or a polydispersity index of more than 0.4 strongly impacts liposome stability.

[0168] Example 14: Preparation of liposomes containing rhamnolipids (according to the invention) To prepare the liposome composition according to Example 14, the lecithin is stirred with the glycerin and the rhamnolipid at a temperature of 85° C. for 60 minutes.

[0169] Water preheated to 85°C is added to the above composition while homogenizing for 4 minutes. Finally, the preservative Optiphen BD is added while homogenizing for an additional minute.

[0170] The final liposome composition contents are as follows; a total of 100 grams is prepared: 5.5% by weight of sunflower lecithin, 25.0% by weight of glycerin, 4.5% by weight of rhamnolipids, 64% by weight of water, 1.0% by weight of preservative Optiphen BD (benzyl alcohol, benzoic acid, dehydroacetic acid).

[0171] The particle size and polydispersity index (PDI) of lipid vesicles produced by this method are confirmed using photon correlation spectroscopy (PCS, Zetasizer Nano ZS90, Malvern Instruments Ltd., UK) according to the manufacturer's instructions; the production process is terminated after the average particle size is approximately 200 nm in diameter and PDI ≦ 0.2.

[0172] Example 15: Preparation of liposomes containing glucolipids (according to the invention) To prepare the liposome composition according to Example 15, lecithin is stirred with glycerin and glucolipid at a temperature of 85° C. for 60 minutes.

[0173] Water preheated to 85°C is added to the above composition while homogenizing for 4 minutes. Finally, the preservative Optiphen BD is added while homogenizing for an additional minute.

[0174] The final liposome composition contents are as follows; a total of 100 grams is prepared: 5.5% by weight of sunflower lecithin, 25.0% by weight of glycerin, 4.5% by weight of glucolipid, 64% by weight of water, 1.0% by weight of preservative Optiphen BD (benzyl alcohol, benzoic acid, dehydroacetic acid).

[0175] The particle size and polydispersity index (PDI) of lipid vesicles produced by this method are confirmed using photon correlation spectroscopy (PCS, Zetasizer Nano ZS90, Malvern Instruments Ltd., UK) according to the manufacturer's instructions; the production process is terminated after the average particle size is approximately 200 nm in diameter and PDI ≦ 0.2.

[0176] Example 16: Preparation of liposomes containing sophorolipids (according to the present invention) To prepare the liposome composition according to Example 16, lecithin is stirred with glycerin and sophorolipid at a temperature of 85° C. for 60 minutes.

[0177] Water preheated to 85°C is added to the above composition while homogenizing for 4 minutes. Finally, the preservative Optiphen BD is added while homogenizing for an additional minute.

[0178] The final liposome composition contents are as follows; a total of 100 grams is prepared: 5.5% by weight of sunflower lecithin, 25.0% by weight of glycerin, 4.5% by weight of sophorolipid, 64% by weight of water, 1.0% by weight of preservative Optiphen BD (benzyl alcohol, benzoic acid, dehydroacetic acid).

[0179] The particle size and polydispersity index (PDI) of lipid vesicles produced by this method are confirmed using photon correlation spectroscopy (PCS, Zetasizer Nano ZS90, Malvern Instruments Ltd., UK) according to the manufacturer's instructions; the production process is terminated after the average particle size is approximately 200 nm in diameter and PDI ≦ 0.2.

[0180] Example 17: Preparation of liposomes containing rhamnolipid and loaded with sphinganine as active ingredient (according to the invention) To prepare the liposome composition according to Example 17, the lecithin is stirred with the glycerin and rhamnolipid for 60 minutes at a temperature of 85° C. The active ingredient is added and stirred for a further 60 minutes.

[0181] Water preheated to 85°C is added to the above composition while homogenizing for 4 minutes. Finally, the preservative Optiphen BD is added while homogenizing for an additional minute.

[0182] The final liposome composition contents are as follows; a total of 100 grams is prepared: 5.5% by weight of sunflower lecithin, 25.0% by weight of glycerin, 4.5% by weight of rhamnolipids, 1.5% by weight of sphinganine, 62.5% by weight of water, 1.0% by weight of preservative Optiphen BD (benzyl alcohol, benzoic acid, dehydroacetic acid).

[0183] The particle size and polydispersity index (PDI) of lipid vesicles produced by this method are confirmed using photon correlation spectroscopy (PCS, Zetasizer Nano ZS90, Malvern Instruments Ltd., UK) according to the manufacturer's instructions; the production process is terminated after the average particle size is approximately 200 nm in diameter and PDI ≦ 0.2.

[0184] Example 18: Preparation of liposomes containing glucolipids and loaded with sphinganine as the active ingredient (according to the invention) To prepare the liposome composition according to Example 18, lecithin is stirred with glycerin and glucolipid for 60 minutes at a temperature of 85° C. The active ingredient is added and stirred for another 60 minutes.

[0185] Water preheated to 85°C is added to the above composition while homogenizing for 4 minutes. Finally, the preservative Optiphen BD is added while homogenizing for an additional minute.

[0186] The final liposome composition contents are as follows; a total of 100 grams is prepared: 5.5% by weight of sunflower lecithin, 25.0% by weight of glycerin, 4.5% by weight of glucolipid, 1.5% by weight of sphinganine, 62.5% by weight of water, 1.0% by weight of preservative Optiphen BD (benzyl alcohol, benzoic acid, dehydroacetic acid).

[0187] The particle size and polydispersity index (PDI) of lipid vesicles produced by this method are confirmed using photon correlation spectroscopy (PCS, Zetasizer Nano ZS90, Malvern Instruments Ltd., UK) according to the manufacturer's instructions; the production process is terminated after the average particle size is approximately 200 nm in diameter and PDI ≦ 0.2.

[0188] Example 19: Preparation of liposomes containing sophorolipids and loaded with sphinganine as an active ingredient (according to the present invention) To prepare the liposome composition according to Example 19, lecithin is stirred with glycerin and sophorolipid for 60 minutes at a temperature of 85° C. The active ingredient is added and stirred for another 60 minutes.

[0189] Water preheated to 85°C is added to the above composition while homogenizing for 4 minutes. Finally, the preservative Optiphen BD is added while homogenizing for an additional minute.

[0190] The final liposome composition contents are as follows; a total of 100 grams is prepared: 5.5% by weight of sunflower lecithin, 25.0% by weight of glycerin, 4.5% by weight of sophorolipid, 1.5% by weight of sphinganine, 62.5% by weight of water, 1.0% by weight of preservative Optiphen BD (benzyl alcohol, benzoic acid, dehydroacetic acid).

[0191] The particle size and polydispersity index (PDI) of lipid vesicles produced by this method are confirmed using photon correlation spectroscopy (PCS, Zetasizer Nano ZS90, Malvern Instruments Ltd., UK) according to the manufacturer's instructions; the production process is terminated after the average particle size is approximately 200 nm in diameter and PDI ≦ 0.2.

[0192] Example 20: List example formulations that include the liposome preparations of Example 2, Example 3, Example 6, Example 9, Example 10, Example 17, Example 18, or Example 19; therefore, eight formulations are prepared for each formulation listed. "Example X" = Example 2, Example 3, Example 6, Example 9, Example 10, Example 17, Example 18, or Example 19.

[0193] 20.1 Cream A 1.50% by weight TEGO® Care 450 MB (Polyglyceryl-3 Methylglucose Distearate) 0.50% by weight of ABIL® Care XL 80 MB (Bis PEG / PPG-20 / 5 PEG / PPG-20 / 5 Dimethicone; Methoxy PEG / PPG-25 / 4 Dimethicone; Caprylic / Capric Triglyceride) 1.50% by weight stearyl alcohol 2.50% by weight of TEGIN® M Pellets MB (glyceryl stearate) 6.50% by weight TEGOSOFT® M (isopropyl myristate) 4.80% by weight TEGOSOFT® APM (PPG-3 myristyl ether) 0.50% by weight TEGOSOFT® MM MB (myristyl myristate) B 1.00% by weight TEGO® Natural Betaine 3.00% by weight glycerin Up to 100% water by weight C 0.20% by weight carbomer 0.10% by weight xanthan gum 0.80% by weight TEGOSOFT® M (isopropyl myristate) D 3.00% by weight of Example X (see above) A suitable amount of sodium hydroxide (10% in water) 1.00% by weight Verstatil® PC (phenoxyethanol; caprylyl glycol) The right amount of fragrance.

[0194] 20.2 Facial masks A 0.50% by weight of ABIL® Care XL 80 MB (Bis PEG / PPG-20 / 5 PEG / PPG-20 / 5 Dimethicone; Methoxy PEG / PPG-25 / 4 Dimethicone; Caprylic / Capric Triglyceride) 1.50% by weight ABIL® 350 (dimethicone) 4.00% by weight TEGOSOFT® OS (ethylhexyl stearate) 4.00% by weight TEGOSOFT® CT MB (caprylic / capric triglyceride) B 0.60% by weight of TEGO® Carbomer 341 ER (Acrylates / C10-30 Alkyl Acrylate Crosspolymer) 0.10% by weight HyaCare® (sodium hyaluronate) 0.10% by weight of HyaCare® 50 (hydrolyzed hyaluronic acid) 5.00% by weight glycerin Up to 100% water by weight C 3.00% by weight of Example X (see above) D 1.00% by weight Verstatil® PC (phenoxyethanol; caprylyl glycol) E A suitable amount of sodium hydroxide (10% in water).

[0195] 20.3 Serum A 0.30% by weight of TEGO® Carbomer 341 ER (Acrylates / C10-30 Alkyl Acrylate Crosspolymer) Up to 100% water by weight B A suitable amount of sodium hydroxide (10% in water) C 1.00% by weight of TEGO® SML 20 MB (Polysorbate 20) 3.00% by weight of Example X (see above) D 2.00% by weight Verstatil® PC (phenoxyethanol; caprylyl glycol).

[0196] 20.4 Cream A Up to 100% by weight deionized water 2.00% by weight Glycerin, 99.5%, Ph. Eur. (Glycerin) 0.10% by weight of dermofeel® PA-3 (sodium phytate; water; alcohol) A1 0.30% by weight of Xanthan Gum FEDCS-PC (Xanthan Gum) B 1.00% by weight of TEGO® Feel C 10 (cellulose) 6.00% by weight of symbio® muls GC MB (glyceryl stearate citrate; cetearyl alcohol; glyceryl caprylate) 6.00% by weight of TEGOSOFT® DC MB (decyl cocoate) 2.00% by weight of dermosoft® decalact sebum MB (Polyglyceryl-10 Laurate; Sodium Caproyl / Lauroyl Lactylate; Glycerin; Serenoa Serrulata Fruit Extract; Juniperus Communis Fruit Extract). 0.10% by weight of dermofeel® Toco 70 non GMO (tocopherol; helianthus annuus (sunflower) seed oil) C 3.00% by weight of dermosoft® 1388 eco (glycerin; water; sodium levulinate; sodium anisate) 3.00% by weight of Example X (see above) 0.15% by weight fragrance.

[0197] 20.5 Lip Mask A 0.02% by weight HyaCare® (sodium hyaluronate) 9.96% by weight glycerin Up to 100% water by weight 0.02% by weight of Rouge Covarine W 3799 (CI 12490; Water; Glycerin) 0.02% by weight of Rouge Covarine W 3799 (CI 12490; Water; Glycerin) B 8.00% by weight of TEGOSOFT® DC MB (decyl cocoate) 2.00% by weight TEGOSOFT® OER MB (oleyl erucate) 3.00% by weight TEGOSOFT® MM MB (myristyl myristate) 7.00% by weight TEGOSOFT® P (isopropyl palmitate) 3.00% by weight ISOLAN® GPS (Polyglyceryl-4 diisostearate / polyhydroxystearate / sebacate) 6.00% by weight of TEGOSOFT® SH MB (Stearyl Heptanoate) 1.00% by weight of Cera Alba 10.00% by weight of candelilla wax (Candella cerata) 3.00% by weight of carnauba wax 3.50% by weight of Butyrospermum Parkii (Shea) Butyrospermum (Shea) Butter 33.49% by weight of SAT-Y-338073 (yellow iron oxide) 33.49% by weight of Schercemol PTID Ester (Polyglyceryl-3 Dimer Dilinoleate Triisostearate) C 2.00% by weight of Example X (see above).

[0198] 20.6. Sleep Mask A 0.50% by weight of ABIL® Care XL 80 MB (Bis PEG / PPG-20 / 5 PEG / PPG-20 / 5 Dimethicone; Methoxy PEG / PPG-25 / 4 Dimethicone; Caprylic / Capric Triglyceride) 1.50% by weight of ABIL® Wax 9840 (cetyl dimethicone) 4.00% by weight TEGOSOFT® OS (ethylhexyl stearate) 4.00% by weight TEGOSOFT® CT MB (caprylic / capric triglyceride) B Up to 100% water by weight 5.00% by weight glycerin 0.05% by weight of KELCOGEL CG-HA (gellan gum) 0.40% by weight of Carbomer (Carbomer Homopolymer C) C 2.00% by weight TEGO® Natural Betaine 0.50% by weight TEGO® Turmerone (Curcuma longa (turmeric) root extract) 2.00% by weight of Example Run X (see above) D A suitable amount of sodium hydroxide (10% in water) E 0.80% by weight of Verstatil® PC (phenoxyethanol; caprylyl glycol).

[0199] 20.7 Body Mask A Up to 100% by weight deionized water 4. 50% by weight Glycerin, 99.5%, Ph. Eur. (Glycerin) 0.10% by weight of dermofeel® PA-3 (sodium phytate; water; alcohol) 0.80% by weight of Xanthan Gum FEDCS-PC (Xanthan Gum) B 5.00% by weight of refined phytosqualane (squalane) derived from olives B1 8.00% by weight of symbio® muls GC MB (glyceryl stearate citrate; cetearyl alcohol; glyceryl caprylate) 2.00% by weight of TEGIN® M Pellets MB (glyceryl stearate) 2.00% by weight KahlWax 8104 (Cera Alba) 2.00% by weight KahlWax 6614 (Camellia Sinensis Leaf Extract) 2.00% by weight of refined organic shea butter (Butyrospermum Parkii butter) 5.00% by weight of refined almond oil (Prunus Amygdalus Dulcis oil) 3.00% by weight of refined avocado oil (Persea Gratissima oil) 2.00% by weight of refined apricot kernel oil (Prunus Armeniaca kernel oil) 0.20% by weight of dermofeel® Toco 70 non GMO (tocopherol; helianthus annuus (sunflower) seed oil) 1.00% by weight of dermofeel® TocoSkin (tocopherol; helianthus annuus (sunflower) seed oil) C 0.50% by weight TEGO® Turmerone (Curcuma longa (turmeric) root extract) 0.50% by weight of pumpkin seed organic extract P-00025487 (helianthus annuus hybrid oil; cucurbita pepo seed extract; rosmarinus officinalis leaf extract) 2.00% by weight of Example X (see above) 3.5% by weight of dermosoft® 1388 eco NaL (glycerin, water, sodium levulinate, p-anisic acid, sodium hydroxide).

[0200] 20.8 Aftershave Serum A Up to 100% by weight deionized water 0.10% by weight of dermofeel® PA-3 (sodium phytate; water; alcohol) 3.00% by weight of dermosoft® OM (methylpropanediol, caprylyl glycol) 5.00% by weight Glycerin, 99.5%, Ph. Eur. (Glycerin) B 2.50% by weight of symbio® prot V MB (hydrolyzed vegetable protein; sodium citrate; magnesium stearate; xanthan gum) 0.50% by weight of TEGIN® M Pellets MB (glyceryl stearate) 4.00% by weight of TEGOSOFT® DC MB (decyl cocoate) 0.50% by weight phytosqualane (squalane) 1.00% by weight of TEGO® Feel C 10 (cellulose) 0.20% by weight of dermofeel® Toco 70 non GMO (tocopherol; helianthus annuus (sunflower) seed oil) 2.00% by weight of dermosoft® decalact sebum MB (Polyglyceryl-10 Laurate; Sodium Caproyl / Lauroyl Lactylate; Glycerin; Serenoa Serrulata Fruit Extract; Juniperus Communis Fruit Extract). C 3.00% by weight denatured ethanol (denatured alcohol) D 2.00% by weight of Example X (see above).

[0201] 20.9 Hair & Scalp Serum A 2.00% by weight TEGO® Care LTP MB (sorbitan laurate; polyglyceryl-4 laurate; dilauryl citrate) 2.67% by weight TEGOSOFT® CT MB (caprylic / capric triglyceride) 1.33% by weight of dermofeel® sensolv MB (isoamyl laurate) 1.00% by weight of Hairflux® (Ceramide NG; Olea Europaea (Olive) Fruit Oil; Ricinus Communis (Castor) Seed Oil) B Up to 100% water by weight 3.00% by weight glycerin C 2.00% by weight of dermofeel® sensolv MB (isoamyl laurate) 0.10% by weight of carbomer (carbomer homopolymer A) 0.10% by weight of Acrylates / C10-C30 Alkyl Acrylate Crosspolymer (Carbomer Copolymer C) D 2.00% by weight water 0.005% by weight TEGO® Pep 3-Boost (Tripeptide-34 Copper) E 2.00% by weight of Example X (see above) F 1.00% by weight of Verstatil® PC (phenoxyethanol; caprylyl glycol) A suitable amount of sodium hydroxide (10% in water).

[0202] 20.10 Low Viscosity Face Serum A 3.00% by weight of TEGO® Care PBS 6 MB (Polyglyceryl-6 Stearate (and) Polyglyceryl-6 Behenate) 0.50% by weight of TEGIN® M Pellets MB (glyceryl stearate) 4.00% by weight TEGOSOFT® DEC (diethylhexyl carbonate) 5.00% by weight of TEGOSOFT® XC MB (Phenoxyethyl Caprylate) 3.00% by weight of dermofeel® sensolv MB (isoamyl laurate) 3.00 wt. % TEGO® SP 13-1 MB (Poly C10-30 Alkyl Acrylate) B Up to 100% water by weight 3.00% by weight glycerin 2.00% by weight of Example X (see above) 0.20% by weight of carbomer (carbomer homopolymer A) 0.10% by weight of HyaCare® 50 (hydrolyzed hyaluronic acid) C A suitable amount of sodium hydroxide (10% in water) D 1.00% by weight Verstatil® PC (phenoxyethanol; caprylyl glycol) Z The right amount of fragrance.

[0203] 20.11 Acne serum A 2.00% by weight of TEGOSOFT® AC MB (isoamyl cocoate) 2.00% by weight TEGOSOFT® OER MB (oleyl erucate) 1.00% by weight octyldodecanol 1.00% by weight of TEGOSOFT® APM (PPG-3 myristyl ether) 0.50% by weight TEGO® Turmerone (Curcuma longa (turmeric) root extract) B 0.50% by weight of TEGO® Carbomer 341 ER (Acrylates / C10-30 Alkyl Acrylate Crosspolymer) 5.00% by weight glycerin 3.00% alcohol by weight Up to 100% water by weight C 1.00% by weight of Example X (see above) A suitable amount of sodium hydroxide Z A moderate amount of preservatives.

[0204] 20.12 O / W aftershave cream A 1.5% by weight of AXOL® C 62 Pellets MB (glyceryl stearate citrate) 2.0% by weight of TEGIN® M Pellets MB (glyceryl stearate) 3.0% by weight TEGO® Alkanol 1618 MB (cetearyl alcohol) 3.5% by weight of TEGOSOFT® TN (C12-15 alkyl benzoate) 2.0% by weight TEGOSOFT® CR MB (cetyl ricinoleate) 1.0% by weight of triisostearin 0.5% by weight TEGOSOFT® MM MB (myristyl myristate) 4.0% by weight cyclopentasiloxane 2.0% by weight of Macadamia Ternifolia seed oil 0.5% by weight tocopheryl acetate B 4.0% by weight glycerin 0.5% by weight Panthenol 0.2% by weight allantoin Up to 100% water by weight C 0.3% by weight of carbomer (carbomer homopolymer B) 1.2% by weight of TEGOSOFT® TN (C12-15 alkyl benzoate) D 0.5% by weight of bisabolol E A suitable amount of sodium hydroxide (10% in water) F 7.0% alcohol by weight G 3.0% by weight of Example X (see above) H 0.7% by weight Euxyl PE 9010 (phenoxyethanol, ethylhexylglycerin) Z The right amount of fragrance.

[0205] 20.13 After Sun Gel A 1.5% by weight TEGOSOFT® liquid (cetearyl ethylhexanoate) 0.6% by weight of ABIL® B 8832 (Bis-PEG / PPG-20 / 20 Dimethicone) B 0.3% by weight of dermosoft® GMCY MB (glyceryl caprylate) 0.5% by weight of TEGO® Cosmo C 250 (1-methylhydantoin-2-imide) 0.03% by weight HyaCare® (sodium hyaluronate) 3.00% by weight glycerin 3.00% by weight butylene glycol Up to 100% demineralized water by weight 0.2% by weight of carbomer (carbomer homopolymer C) 0.7% by weight Aristoflex® HMB (ammonium acryloyldimethyltaurate, beheneth-25 methacrylate crosspolymer) C 1.00% by weight of dermosoft® Hexiol (1,2-hexanediol) 3.00% by weight of Example X (see above) A suitable amount of sodium hydroxide 0.25% by weight Red 28 (0.02% in water).

[0206] 20.14 SPF15 Cream A 3.00% by weight of TEGO® Care PBS 6 MB (Polyglyceryl-6 Stearate (and) Polyglyceryl-6 Behenate) 8.00% by weight of TEGOSOFT® XC MB (Phenoxyethyl Caprylate) 5.00% by weight TEGOSOFT® DEC (diethylhexyl carbonate) 3.00% by weight of TEGIN® M Pellets MB (glyceryl stearate) 2.00% by weight TEGO® Alkanol 1618 MB (cetearyl alcohol) 1.00% by weight TEGOSOFT® MM MB (myristyl myristate) 0.50% by weight ABIL® 350 (dimethicone) 0.50% by weight of TEGO® Feel C 10 (cellulose) 2.50% by weight of diethylamino hydroxybenzoyl hexyl benzoate 6.00% by weight Homosalate 0.50% by weight tocopheryl acetate B 11.58% by weight water 0.42% by weight sodium hydroxide 3.00% by weight Eusolex 232 (phenylbenzimidazole sulfonic acid) C Up to 100% water by weight 3.00% by weight glycerin 1.00% by weight TEGO® Pep 4-17 MB (Tetrapeptide-21; Glycerin; Butylene Glycol; Water) 0.50% by weight TEGO® Cosmo C 100 (creatine) D 0.70% by weight Keltrol CG-SFT (xanthan gum) E 2.00% by weight of Example X (see above) 1. 10% by weight of Verstatil® PC (phenoxyethanol; caprylyl glycol) 0.50% by weight fragrance.

[0207] 20.15 SPF20 hand cream A 1.50% by weight of TEGO® Care PBS 6 MB (Polyglyceryl-6 Stearate (and) Polyglyceryl-6 Behenate) 2.50% by weight of VARISOFT® TA 100 (distearyldimonium chloride) 2.00% by weight stearyl alcohol 2.00% by weight of TEGIN® M Pellets MB (glyceryl stearate) 1.00% by weight of TEGOSOFT® SH MB (Stearyl Heptanoate) 5.00% by weight of TEGOSOFT® TN (C12-15 alkyl benzoate) 3.00% by weight of diethylamino hydroxybenzoyl hexyl benzoate 3.00% by weight ethylhexyl salicylate 5.00% by weight ethylhexyl methoxycinnamate 0.50% by weight tocopheryl acetate B Up to 100% water by weight 3.00% by weight glycerin C 1.50% by weight nylon-12 D 2.00% by weight TEGO® Natural Betaine 2.00% by weight water E 2.00% by weight of Example X (see above) A moderate amount of preservatives 0.50% by weight of fragrance "Azura 231517".

[0208] 20.16 SPF30 sun care lotion + insect repellent A 3.50% by weight of TEGO® Care PBS 6 MB (Polyglyceryl-6 Stearate (and) Polyglyceryl-6 Behenate) 2.00% by weight of TEGOSOFT® DC MB (decyl cocoate) 1.00% by weight of TEGOSOFT® TN (C12-15 alkyl benzoate) 0.50% by weight of REWOPAL® PIB 1000 (polyisobutene) 0.50% by weight of TEGIN® M Pellets MB (glyceryl stearate) 0.50% by weight stearyl alcohol 15.00% by weight of Insect Repellent 3535 (ethyl butylacetylaminopropionate) 3.00% by weight Tinosorb S (bis-ethylhexyloxyphenol methoxyphenyl triazine) 3.00% by weight ethylhexyl salicylate 6.00% by weight Homosalate 8.00% by weight Octocrylene 2.00% by weight butyl methoxydibenzoylmethane 2.00% by weight ethylhexyl methoxycinnamate B Up to 100% water by weight 3.00% by weight glycerin C 0.60% by weight of Sepigel 305 (Polyacrylamide (and) C13-14 Isoparaffin (and) Laureth-7) D 2.00% by weight of Example X (see above) 0.70% by weight EUXYL PE 9010 (phenoxyethanol; ethylhexylglycerin) Z The right amount of fragrance.

[0209] 20.17 O / W Foundation A 4.00% by weight of TEGO® Care PBS 6 MB (Polyglyceryl-6 Stearate (and) Polyglyceryl-6 Behenate) 1.50% by weight TEGO® Alkanol 1618 MB (cetearyl alcohol) 1.00% by weight of TEGIN® M Pellets MB (glyceryl stearate) 1.00% by weight TEGOSOFT® MM MB (myristyl myristate) 3.00% by weight of TEGOSOFT® TN (C12-15 alkyl benzoate) 2.00% by weight TEGOSOFT® DEC (diethylhexyl carbonate) 2.00% by weight of 9045 Silicone Elastomer Blend (Cyclopentasiloxane (and) Dimethicone Crosspolymer) 8.00% by weight ethylhexyl methoxycinnamate 5.00% by weight ethylhexyl salicylate 3.00% by weight of diethylamino hydroxybenzoyl hexyl benzoate 3.00% by weight of bis-ethylhexyloxyphenol methoxyphenyl triazine (bis-ethylhexyloxyphenol methoxyphenyl triazine) B Up to 100% by weight deionized water 1.00% by weight glycerin 0.15% by weight xanthan gum C 8.00% by weight of titanium dioxide; CI 77891 1.70% by weight of Covarine Yellow WN 1792 GZ (CI 77492, water, glycerin, xanthan gum, sodium citrate) 0.40% by weight of Covarine Red WN 3798 GZ (CI 77491, Water, Glycerin, Xanthan Gum, Sodium Citrate) 0.10% by weight of Covarine Black WN 9798 GZ (CI 77499, water, glycerin, xanthan gum, sodium citrate) 2.00% by weight glycerin 3.00% by weight propylene glycol D 2.00% by weight Nylon-12 E 2.00% by weight of Example X (see above) 0.70% by weight of Euxyl PE 9010 (phenoxyethanol, ethylhexylglycerin).

[0210] 20.18 Face Care Mousse A 2.50% by weight of ABIL® Care XL 80 MB (Bis PEG / PPG-20 / 5 PEG / PPG-20 / 5 Dimethicone; Methoxy PEG / PPG-25 / 4 Dimethicone; Caprylic / Capric Triglyceride) 5.00% by weight dimethicone (5mPas) 4.00% by weight TEGOSOFT® DEC (diethylhexyl carbonate) 3.00% by weight TEGOSOFT® CT MB (caprylic / capric triglyceride) 1.00% by weight TEGOSOFT® CR MB (cetyl ricinoleate) B 4.00% by weight TEGO® Pep UP (Tetrapeptide-4; Glycerin) 0.50% by weight TEGO® Cosmo C 100 (creatine) 0.50% by weight Panthenol 0.20% by weight allantoin Up to 100% water by weight C 1.60% by weight TEGOSOFT® OS (ethylhexyl stearate) 0.15% by weight of carbomer (carbomer homopolymer A) 0.15% by weight of carbomer (carbomer homopolymer C) 0.10% by weight Keltrol CG-SFT (xanthan gum) D A suitable amount of sodium hydroxide (10% in water) E 1.00% by weight TEGO® Betain 810 MB (capryl / capramidopropyl betaine) 1.00% by weight of REWOTERIC® AM C MB (sodium cocoamphoacetate) 2.00% by weight of Example X (see above) 0.70% by weight Euxyl PE 9010 (phenoxyethanol, ethylhexylglycerin) Z The right amount of fragrance.

[0211] 20.19 Face masks A 1.00% by weight of TEGOSOFT® PC 41 MB (Polyglyceryl-4 Caprate) 1.30% by weight of TEGO® Betain 810 MB (capryl / capramidopropyl betaine) 1.00% by weight of TEGO® Solve 61 MB (Polyglyceryl-6 Caprylate; Polyglyceryl-3 Cocoate; Polyglyceryl-4 Caprate; Polyglyceryl-6 Ricinoleate) 1.00% by weight glycerin 1.40% by weight hexylene glycol B 0.50% by weight of TEGO® Carbomer 140 2.00% by weight TEGO® Natural Betaine Up to 100% water by weight 0.10% by weight xanthan gum C 2.50% by weight of TEGO® Feel C 10 (cellulose) 0.50% by weight TEGO® Turmerone (Curcuma longa (turmeric) root extract) 3.00% by weight of Verstatil® BOB (Benzyl Alcohol; Caprylyl Glycol; Benzoic Acid) 2.00% by weight of Example X (see above) Appropriate weight percent of sodium hydroxide (10% in water).

[0212] 20.20 Aftershave Cream A 2.00% by weight of AXOL® C 62 Pellets MB (glyceryl stearate citrate) 2.00% by weight of TEGIN® M Pellets MB (glyceryl stearate) 3.00% by weight TEGO® Alkanol 1618 MB (cetearyl alcohol) 4.00% by weight TEGOSOFT® DEC (diethylhexyl carbonate) 3.50% by weight of TEGOSOFT® DC MB (decyl cocoate) 2.00% by weight TEGOSOFT® CR MB (cetyl ricinoleate) 1.00% by weight of TEGOSOFT® OER MB (oleyl erucate) 0.50% by weight TEGOSOFT® MM MB (myristyl myristate) 2.00% by weight of Macadamia Ternifolia seed oil 0.50% by weight tocopheryl acetate 0.50% by weight of bisabolol 0.50% by weight of dermosoft® GMCY MB (glyceryl caprylate) B Up to 100% water by weight 4.0% by weight glycerin 0.50% by weight Panthenol 0.20% by weight allantoin C 0.40% by weight Keltrol CG-SFT (xanthan gum) D 7.00% alcohol by weight E 2.00% by weight of Example X (see above) 1.50% by weight of Verstatil® SL non GMO (water; sodium levulinate; potassium sorbate).

[0213] 20.21 Skin Tonic A Up to 100% by weight deionized water 4.00% by weight Glycerin, 99.5%, Ph. Eur. (Glycerin) 0.50% by weight of Ajidew NL-50N (sodium PCA; water) 0.10% by weight of dermofeel® PA-3 (sodium phytate; water; alcohol) B 1.50% by weight of symbio® solv clear plus MB (caprylyl / capryl glucoside; water; sodium cocoyl glutamate; glyceryl caprylate; citric acid; polyglyceryl-6 oleate; sodium surfactin) 1.00% by weight of dermosoft® decalact liquid MB (sodium caproyl / lauroyl lactylate; triethyl citrate) 25.00% by weight denatured ethanol (denatured alcohol) 0.30% by weight fragrance 2.00% by weight of dermofeel® TEC eco (triethyl citrate) C 2.00% by weight of Example X (see above).

[0214] 20.22 Hair and body shampoo 2.25% by weight RHEANCE® One (glycolipid) 0.50% by weight of dermofeel® sensolv MB (isoamyl laurate) 9.70% by weight of lauryl glucoside, 50% 20.00% by weight of coconut alkyl glucoside (50%) 5.50% by weight of sodium cocoyl sulfate, 91% Up to 100.00% water by weight 6.80% by weight glycerin 3.50% by weight of dermosoft® 1388 eco (glycerin; water; sodium levulinate; sodium anisate) 1.05% by weight of TEGO® Remo 95 MB (sorbitan caprylate, glyceryl oleate) 2.00% by weight of Example X (see above) Adjust pH with citric acid.

[0215] 20.23 Micellar water for face washing 2.00% by weight TEGO® Solve 55 MB (Polyglyceryl-3 Caprylate / Caprate / Succinate; Propylene Glycol) 1.30% by weight of TEGO® Betain 810 MB (capryl / capramidopropyl betaine) 0.05% by weight fragrance Up to 100.0% water by weight 2.00% by weight TEGO® Natural Betaine 1.40% by weight hexylene glycol 1.00% by weight glycerin 2.00% by weight of Example X (see above) A moderate amount of preservatives.

[0216] 20.24 Leave-in hair conditioner A 5.00% by weight of TEGO® Sulfosuccinate DO 75 (sodium diethylhexyl sulfosuccinate) 10.00% by weight of dermofeel® sensolv MB (isoamyl laurate) 48.00% by weight of TEGOSOFT® TN (C12-15 alkyl benzoate) 30.00% by weight of Helianthus annuus (sunflower) seed oil B 5.00% by weight of TEGOSOFT® PC 31 MB (Polyglyceryl-3 Caprate) 1.00% by weight of VARISOFT® EQ 100 (bis(isostearoyl / oleoylisopropyl)dimonium methosulfate) 1.00% by weight of Example X (see above).

[0217] 20.25 W / O Lotion A 2.5% by weight ISOLAN® GPS (Polyglyceryl-4 diisostearate / polyhydroxystearate / sebacate) 10.0% by weight TEGOSOFT® DEC (diethylhexyl carbonate) 9.0% by weight TEGOSOFT® OP (ethylhexyl palmitate) 0.5% by weight zinc stearate B Up to 100.0% water by weight 3.0% by weight glycerin 1.5% by weight magnesium sulfate heptahydrate 2.0% by weight of Example X (see above) Z Appropriate amount of preservatives and fragrances

Claims

1. below: A) at least one phospholipid present at least partially in the bilayer of the liposome; B) at least one biosurfactant; C) water, and optionally D) at least one solvent selected from the group of alcohols and polyols containing at least 3 carbon atoms; A liposome composition comprising:

2. 2. The composition of claim 1, wherein the at least one phospholipid is selected from phosphatidylcholine, phosphatidylethanolamine, phosphatidic acid, phosphatidylserine, phosphoinositides, and phosphosphingolipids.

3. 2. The composition of claim 1, wherein the at least one biosurfactant is selected from rhamnolipids, sophorolipids and glucolipids.

4. 2. The composition of claim 1, wherein said at least one solvent is selected from the alcohols of the group consisting of alkanols and alkenols.

5. The composition of claim 1 , wherein the at least one solvent is selected from diols and triols.

6. The composition comprises:

10. The composition according to claim 1, characterized in that it comprises E) at least one cosmetic, pharmaceutical and / or nutraceutical active ingredient.

7. 7. The composition according to claim 6, characterized in that the at least one cosmetic, pharmaceutical and / or nutraceutical active ingredient is selected from the group consisting of ceramides, sphingoid bases, sterols, peptides, amino acids, phenols, polyphenols, vitamins, plant or algal extracts and cosmetic oils.

8. 7. The composition according to claim 6, characterized in that the composition comprises as component E) at least one ceramide and cholesterol.

9. The composition comprises: A) in an amount of 0.1% to 60% by weight, B) in an amount of 0.1% to 60% by weight, C) in an amount of 10% to 95% by weight, optionally D) in an amount of 0.1% to 80% by weight, and optionally E) in an amount of 0.05% to 20% by weight 2. The composition of claim 1, wherein the weight percentages are based on the total composition.

10. 2. The composition according to claim 1, wherein the liposomes contained therein have an average particle size of 15 nm to 800 nm.

11. A formulation comprising at least one liposome composition according to any one of claims 1 to 10.

12. The formulation comprises: A) in an amount of 0.0001% to 6% by weight, B) in an amount of 0.0001% to 6% by weight, C) in an amount of 20% to 99% by weight, optionally D) in an amount of 0.0001% to 30% by weight, and optionally E) in an amount of 0.00005% to 40% by weight 12. The formulation according to claim 11, characterized in that it comprises, wherein the weight percentages are based on the total formulation.

13. 1. A method for encapsulating at least one cosmetic, pharmaceutical and / or nutraceutical active ingredient, comprising: I) providing and combining at least one phospholipid A), at least one biosurfactant B), at least one cosmetic, pharmaceutical and / or nutraceutical active ingredient E), and optionally at least one solvent D) selected from the group of alcohols and polyols containing at least 3 carbon atoms; II) heating the provided ingredients to a temperature in the range of 50°C to 100°C; III) heating water C) to a temperature ranging from 50°C to 100°C and combining said water with the ingredients provided in step I); A method comprising:

14. 11. Use of at least one composition according to any one of claims 1 to 5 and 10 for encapsulating at least one cosmetic, pharmaceutical and / or nutraceutical active ingredient.